Welcome to our dedicated page for Surgery Partners news (Ticker: SGRY), a resource for investors and traders seeking the latest updates and insights on Surgery Partners stock.
Surgery Partners Inc (SGRY) operates a national network of surgical facilities and complementary healthcare services, delivering integrated outpatient care solutions. This page serves as the definitive source for verified company announcements, financial updates, and operational developments.
Key resources for stakeholders include earnings reports, partnership announcements, facility expansions, and regulatory filings. Our curated news collection enables investors to track strategic initiatives in ambulatory surgery centers, diagnostic services, and specialty care programs.
Regular updates cover operational milestones, leadership changes, and industry recognition. All content undergoes strict verification to ensure accuracy and relevance for healthcare investors and sector analysts.
Bookmark this page for streamlined access to SGRY's latest developments in surgical innovation and outpatient care delivery. Combine real-time updates with historical context for informed decision-making.
Surgery Partners (NASDAQ:SGRY), a leading short-stay surgical facility operator, has announced the release date for its second quarter 2024 earnings report. The company will disclose its financial results before the market opens on Tuesday, August 6, 2024, followed by a conference call at 8:30 a.m. Eastern Time.
Investors can access the live call by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international) with the Conference ID: SPI2Q24. A replay will be available for two weeks after the call. Additionally, a simultaneous webcast will be accessible through the Investor Relations section of the company's website at www.surgerypartners.com.
Surgery Partners, Inc. reported strong financial results for the first quarter of 2024, with revenues increasing by 7.7% to $717.4 million. The company's same-facility revenues grew by 10.2%, while the net loss was $12.4 million. Adjusted EBITDA reached $97.5 million, with an 8.2% growth compared to the previous year. The company raised its full-year 2024 guidance to at least $3.05 billion in revenue and at least $505 million in Adjusted EBITDA. Surgery Partners' executives highlighted strong growth driven by clinical quality, operational execution, and strategic acquisitions.
FAQ
What is the current stock price of Surgery Partners (SGRY)?
What is the market cap of Surgery Partners (SGRY)?
